EGFR and hepatocellular carcinoma: For example, the dual PI3K/mTOR inhibitor PKI-587 was shown to radiosensitize HCC cells in vivo98 and combined BKM and panitumumab (human EGFR antibody) or MEK Inhibitor Binimetinib treatments showed promising results in CRC patients 99,100.